ppt uts (2)

8/17/2019 PPT UTS (2)

1/85

Herbal Antipyretic

Ayu Gayatri Sistiaf (1306447663)

Diana Christina (130637090)

Getta Austin !an"irin" (130640#364)

$a%ia &ua%a A'nan (13064134)

$a%ira utri inasthia (1306370*14)Satria asthia (1306371041)

8/17/2019 PPT UTS (2)

2/85

+,&-.$/

Introduction

Literature References

Needs and Ideas

Product Specications

Creating Concept

Concept Selection

Conclusion

8/17/2019 PPT UTS (2)

3/85

.$&+D,C&.+$

8/17/2019 PPT UTS (2)

4/85

ac"r2un%

• eer is a c2n%iti2n5here the b2%yteperature rises in5hich it is c2ntr2llableat frst but be"ins t2

cause physical%isc2'2rt 5hen itreaches 398#2C8

• Antipyretic %ru"s 52rby l25erin" the

teperature stan%ar%st2 its n2ral alue8

• Synthetic antipyretic%ru"s ay haeseeral si%e eects

such as peptic ulcers%u2%enu ulcersi%ney %is2r%ers an%lier8 urther2rethey ay be a

e:pensie in price5hich pushes pe2plet2 use tra%iti2nale%icine instea%5hich are 2resiple an% a2r%ableyet ;ust as eectie inters 2' preenti2nan% treatent8

8/17/2019 PPT UTS (2)

5/85

ac"r2un%

• Herbal treatent usin"e%icinal plants has beenepirically pr2eneectie '2r treatin" the%isease8 .n%2nesia has a5ealth 2' %ierse bi2l2"ical

res2urces an% any 2'the c2ntain use'ul %ru"s8

• &ra%iti2nal e%icine is thenatural e%icine that hasbeen use% '2r a"es an%n25n '2r its use'ulness in

stren"thenin" the iunesyste as 5ell as t2 c2pe5ith ari2us %iseases8

• ase% 2n .n%2nesia

'rien%ly anner8 &hispr2%uct 5ill als2 bee:pecte% t2 s2le a;2rpr2ble? the sypt2

8/17/2019 PPT UTS (2)

6/85

r2ble

.%entifca

18 Syntheticantipyretic %ru"s ay

cause si%e eectssuch as "astric ulcers%u2%enal ulcers

ipaire% i%ney an%lier %aa"e8

8 Syntheticantipyretic %ru"s ayre@uire lar"er %2ses t2

achiee sustainable

'eer re%ucti2n suchthat it is n2t eectie8

8/17/2019 PPT UTS (2)

7/85

r2ble

2un%a

18 Herbal antipyretics 5ill beuse% t2 treat 'eer cause% by

'ati"ue an% c2l%8

8 Herbal antipyretics 5ill becreate% usin" 100= herbalin"re%ients that re%uce the

ne"atie ipacts t2 thec2nsuers health c2n%iti2n8

38 &he aret tar"et 2' thispr2%uct 5ill be a%ults (B 1#

years 2l%)8

48 &he antipyretic create% 5illbe a pr2%uct a%e 'r2 ne5

i%eas8

8/17/2019 PPT UTS (2)

8/85

-.&/A&,/ ///$C/S

8/17/2019 PPT UTS (2)

9/85

Pyrogenicactivators:infection,microbial

toxins,mediators ofinammation

, immunereactions

!onocytes"macrop#age

s,endot#elialcells, ot#ers

$ndogenouspyrogens"

Pyrogeniccyto%ines IL&',(, )N*,I*N,!IP&'

$xogenendogpyroge

stimu

endot##ypot#

s to prosta

n

!echanis 2' eer

8/17/2019 PPT UTS (2)

10/85

)#atprostaglandin illincrease

t#ermosta

t set pointin#ypot#ala

mict#ermo&

regulatorycenter-

.ypot#alamus Central/mediators

of fever0 illassume t#at

currenttemperature

is loert#an ne

temperatureset point

$levated

t#ermo&regulatoryset point

!ec#anism to

increaset#ermal

.eatconservation, #eat

production

!echanis 2' eer

P armaceut ca !e cat on Non

8/17/2019 PPT UTS (2)

11/85

2inger / Zingiber ofcinale0•

Actie c2p2un% ? "in"er2l• !eth2% 2' e:tractin" ? %istillati2n an% s

%istillati2n

Leng%uas / Alpinia galanga0• Actie c2p2un% ? "alan"2is2a2n2i%• !eth2% 2' e:tractin" ? fltrati2n

3encur /Kaemperia galang• Actie c2p2un% ? ethyl>p>eth2:ycin• !eth2% 2' e:tractin" ? fltrati2n

*everfe /Tanacetum parthenium0• Actie c2p2un% ? ses@uiterpene lact2• !eth2% 2' e:tractin" ? e:tracti2n 5ith

acet2nitrile 5ater 90?10

Aspirin

Acetain2phen (paraceta2l)

.bupr2'en

Sp2n"in" ,n%ress

a bit Ere2ee:cesscl2thes

Set the

teperaturet2 ac2'2rtable

leel

Stay

hy%rate%an% eatri"ht

P armaceut ca !e cat on, Non&P#armaceutical )reatment, .erbal 4n

Pyretic

8/17/2019 PPT UTS (2)

12/85

$//DS A$D .D/AS

8/17/2019 PPT UTS (2)

13/85

Characteristics 2' esp2n%ents

8/17/2019 PPT UTS (2)

14/85


8/17/2019 PPT UTS (2)

15/85


8/17/2019 PPT UTS (2)

16/85


8/17/2019 PPT UTS (2)

17/85

8/17/2019 PPT UTS (2)

18/85


8/17/2019 PPT UTS (2)

19/85

/:pectati2n 2' $e5 r2%uct

8/17/2019 PPT UTS (2)

20/85


8/17/2019 PPT UTS (2)

21/85


$ssential

8/17/2019 PPT UTS (2)

22/85

$ee%s?Gr2upin" an% ranin"

• an .n%icat2r?

$ssential

&he nee%s are 2bli"e% t2 bepresent in the %esi"ne%pr2%uct.ig#ly 5esirable

&he nee%s are seen ase:pecte% benefts by 2stc2nsuersNice to .ave

&he nee%s can be sai% as anFe:citeent nee%

Not Important

&he nee%s are less ur"ent '2r2ur "2als

6ndesirable

the nee%s are n2t reallyip2rtant 2r are n2t suitable5ith 2ur "2als

2int epresent

# /ssential

4 Hi"hlyDesirable

3 $ice t2 Hae

$2t.p22rtant

1 ,n%esirable

8/17/2019 PPT UTS (2)

23/85

-ist 2' $ee%s

$28 $ee%s an

/ssential

1 Herbal e%icine 5hich 52rs 'ast #

4

Herbal e%icine 5hich 52rs eectiely #13

1#

1*Herbal e%icine 5ith2ut artifcial

s5eetener #

7 Herbal e%icine 5hich aailable in anyl2cal st2res

#17

9

Herbal e%icine 5hich is a2r%able #16

8/17/2019 PPT UTS (2)

24/85

-ist 2' $ee%s$28 $ee%s an

Hi"hly Desirable6 Herbal e%icine 5hich has practical '2r 4

9 Herbal e%icine 5hich is s5eet 4 $ice t2 hae7 Herbal e%icine 5hich easy t2 c2nsue 3

1Herbal e%icine 5hich re%uce "astricaci%

3

11 Herbal e%icine 5hich is less isc2us 3 $2t ip2rtant

16 Herbal e%icine 5hich is less bitter 0

Herbal e%icines a2r as it is

1 ,n%esirable

8/17/2019 PPT UTS (2)

25/85

+D,C& S/C..CA&.+$

-ist 2'

8/17/2019 PPT UTS (2)

26/85

No

Needs !etrics !etrics 6nit

Ingredients

'7

Herbal e%icine has n2 artifcials5eetener

Artifcials5eetener

c2ncentrati2n"serin"

Product Performance

'Herbal e%icine 5hich 52rs

@uicly

&ie taen t2 heal Days8

Herbal e%icine 5hich 52rseectiely

'9'';

Herbal e%icine 5hich re%uces"astric aci%

Herbs ActieC2ncentrati2n =

''

Herbal e%icine 5hich is lessisc2us

Iisc2sity "rs8c

-ist 2'!etrics

-i t ' ! t i ( t)

8/17/2019 PPT UTS (2)

27/85

Product Perception'

<

Herbal e%icine 5hich is less

bitter

la2r Sub;ectie

Herbal e%icine 5hich iss5eet

S5eetenerC2ncentrati2n

"serin"

7'8'

=;< Herbal e%icines a2r as it

isla2r Sub;ectie

;'

Retailing

> Herbal e%icine 5hichaailable in any l2cal st2res

Distributi2n ,nityear'>=

-ist 2' !etrics (c2nt)

Specifcati2n 2' r2%uct

8/17/2019 PPT UTS (2)

28/85

Specifcati2n 2' r2%uct

No-

Needs

Concentration

*orm

)ime

ta% ento#e

al

5

esign

!as

s+1olume

5i

mension

1i

scosity

5

s

tr

buto

n

.erbs4ctive

4rticialSeetene

r

S

eetene

r

Ingredients

'7Herbal e%icine 5hich has

n2 artifcial s5eetenerJ J

Product Performance

' Herbal e%icine 5hich52rs @uicly

J J

8Herbal e%icine 5hich

Specifcati2n 2' r2%uct (c2nt)

8/17/2019 PPT UTS (2)

29/85

Pac%aging( Herbal e%icine 5hich has

practical '2r an% easy t2

c2nsue

J J J;

9Product Perception

'<Herbal e%icine 5hich is less

bitter J J

Herbal e%icine 5hich is

s5eetJ J J

7'8'=;< Herbal e%icines a2r as it

isJ J J

;'Retailing


J'>

= Herbal e%icine 5hich isa2r%able

'(;;

Specifcati2n 2' r2%uct (c2nt)

enchar -ist

8/17/2019 PPT UTS (2)

30/85

enchar -ist

No-

!etrics!etrics

6nit?n

)ola%4ngin

Sidomunc

ul

Paracetamol

)ablets

Ibuprof en

)ablet

Ingredients

'7Artifcial

s5eetenerc2ncentrati2n

"serin" 0 0 0 0

Product Performance'

&ie taen t2heal

Days 1# 1 8

'9'

';Herbs Actie

C2ncentrati2n= 100 30 0 0

'' Iisc2sity "rs8c J JJ JJJJJ JJJJJ

Pac%aging

( 2r Sub;ectie 10 l 1# l 10 tablets10

tablets

enchar -ist (c2nt)

8/17/2019 PPT UTS (2)

31/85

Product Perception'<

la2r Sub;ectie J JJ J J;=

rice upiahp

800000p

3800000p

1847000p

876*00 '(;;

enchar -ist (c2n t)

&able 2' .%eal Ialue E !ar"inal Ia

8/17/2019 PPT UTS (2)

32/85

&able 2' .%eal Ialue E !ar"inal IaNo-

!etrics !etrics 6nit Ideal 1alue!arginal

1aluePaten

Ingredients

'7Artifcial


"serin" #00>3000K *00>1000

Surat LepLepala a%

$2H8L80080#8#

Product Performance'

&ie taen t2heal Days > 1> >8'9'

';Herbs Actie

C2ncentrati2n= > #670>16#01 >

'' Iisc2sity "rs8c > JJ >Pac%aging

( 2r Sub;ectie Sub;ectie Sub;ectie Sub;ec

; Diensi2n c : c : c >(9>17) :

(#7# M 6#) : >

&able 2' .%eal Ialue E !ar"inal Ia

8/17/2019 PPT UTS (2)

33/85

Product Perception'<

la2r Sub;ectie Sub;ectie Sub;ectie Sub;ect;<;'

S5eetenerC2ncentrati2n

"serin" #00>3000K *00>1000

Surat LepuLepala a%

$28H8L80080#8#

7'8'=

Retailing>

Distributi2n ,nityear > 7*680008000 >'>=

rice upiah >p 1847000

M p3800000

Sure'(

&able 2' .%eal Ialue E !ar"inal Ia(c2nt)

&able 2' r2%uct Specifcati2n

8/17/2019 PPT UTS (2)

34/85

&able 2' r2%uct Specifcati2nNo Needs !etrics !etrics 6nit Ran%

Ingredients

'7 Herbal e%icine 5hich has n2artifcial s5eetener

Artifcial


"serin" #

Product Performance

'Herbal e%icine 5hich 52rs

'ast &ie taen t2

healDays #8

Herbal e%icine 5hich 52rseectiely'9

'

';Herbal e%icine 5hich re%uce

"astric aci%Herbs Actie

C2ncentrati2n=

''Herbal e%icine 5hich is less

isc2usIisc2sity "rs8c 3

Pac%aging(

Herbal e%icine 5hich haspractical '2r an% easy t2

2r Sub;ectie 4

; Diensi2n c : c : c

Product Perception

'<Herbal e%icine 5hich is less

la2r Sub;ectieSu

&able 2' r2%uct Specifcati2n (c2n

8/17/2019 PPT UTS (2)

35/85

'<bitter

la2r Sub;ectie

Herbal e%icine 5hich is

s5eetS5eetener

C2ncentrati2n"serin"

7'8

'=;< Herbal e%icines a2r as itis

la2r Sub;ectieSu

;'Retailing


Distributi2n ,nityear # 40'>

=Herbal e%icine 5hich is

a2r%ablerice

&able 2' r2%uct Specifcati2n (c2n

8/17/2019 PPT UTS (2)

36/85

Creatin" C2ncept

8/17/2019 PPT UTS (2)

37/85

8/17/2019 PPT UTS (2)

38/85

•How does the product specifications of existing Antipyretic Herbal Bas

Medicine market needs today?•

How to design Antipyretic Herbal causes by fatigue and cold that haveeffectiveness even better than existing Antipyretic nowadays?•What kind of innovation replacement of Herbal Antipyretic will be acce

by consumers?•ould we use herbal active compound rather than chemical to make

Antipyretic Medicine?•How to designHerbal Antipyretic that has less harm side effect than ex

Antipyretic nowadays?•How to design Herbal Antipyretic that practice and easy to use than ex

Antipyretic nowadays?•What is main problem in Antipyretic Herbal Based Medicine manufact

/:istin" .%ea

8/17/2019 PPT UTS (2)

39/85

/:istin" .%ea

$e5 .%ea

8/17/2019 PPT UTS (2)

40/85

$e5 .%ea

C2binin" Herbal

8/17/2019 PPT UTS (2)

41/85

"Antipyretic

!in%ap C2ncept

.%eas $uber C2ncept rAnti>pyretic %ru" 5ith paraceta2l as cheical actie

8/17/2019 PPT UTS (2)

42/85

araseta2lAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' syrup8

.bupr2'enAnti>pyretic %ru" 5ith ibupr2'en as cheical actiec2p2un% an% 5ith the echanis 2' ipe%in"

pr2sta"lan%ins in the '2r 2' syrup8

1st i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' syrup8

n% i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' interleuin>1inhibit2r in the '2r 2' syrup8

3r% i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' anti>histaine inthe '2r 2' syrup8

4th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' inin anta"2nisin the '2r 2' syrup8

#th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' leu2trienesinhibit2r in the '2r 2' syrup8Anti>pyretic %ru" 5ith ibupr2'en as cheical actie

.%eas $uber C2ncept r

9th i%Anti>pyretic %ru" 5ith ibupr2'en as cheical actie

% % ith th h i ' i i t i i

8/17/2019 PPT UTS (2)

43/85

9th i%ea c2p2un% an% 5ith the echanis 2' inin anta"2nis inthe '2r 2' syrup8

10th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actiec2p2un% an% 5ith the echanis 2' leu2trienesinhibit2r in the '2r 2' syrup8

11th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' capsule8

1th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' interleuin>1inhibit2r in the '2r 2' capsule8

13th i%ea Anti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' anti>histaine inthe '2r 2' capsule8

14th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' inin anta"2nis inthe '2r 2' capsule8

1#th i%ea

Anti>pyretic %ru" 5ith paraceta2l as cheical actie

c2p2un% an% 5ith the echanis 2' leu2trienesinhibit2r in the '2r 2' capsule8

th

Anti>pyretic %ru" 5ith ibupr2'en as cheical actie

.%eas $uber C2ncept rAnti>pyretic %ru" 5ith ibupr2'en as cheical actie

8/17/2019 PPT UTS (2)

44/85

19th i%eapy " p

c2p2un% an% 5ith the echanis 2' inin anta"2nisin the '2r 2' capsule8

0th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actiec2p2un% an% 5ith the echanis 2' leu2trienes

inhibit2r in the '2r 2' capsule8

1st i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' tablet8

n% i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' interleuin>1inhibit2r in the '2r 2' tablet

3r% i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' anti>histaine inthe '2r 2' tablet8

4th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actiec2p2un% an% 5ith the echanis 2' inin anta"2nisin the '2r 2' tablet8

#th i%ea

Anti>pyretic %ru" 5ith paraceta2l as cheical actie

c2p2un% an% 5ith the echanis 2' leu2trienesinhibit2r in the '2r 2' tablet8Anti>pyretic %ru" 5ith ibupr2'en as cheical actie

.%eas $uber C2ncept Anti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p2un%

8/17/2019 PPT UTS (2)

45/85

9th i%ea an% 5ith the echanis 2' inin anta"2nis in the '2r 2'tablet8

30th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p2un%an% 5ith the echanis 2' leu2trienes inhibit2r in the '2r

2' tablet8

31st i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbalactie c2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' in'usin" ba"8

3n% i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbalactie an% 5ith the echanis 2' interleuin>1 inhibit2r in the'2r 2' in'usin" ba"8

33r% i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbalactie an% 5ith the echanis 2' anti>histaine in the '2r2' in'usin" ba"8

34th i%eaAnti>pyretic %ru" 5ith a2nes as herbal actie c2p2un% an%5ith the echanis 2' leu2trienes inhibit2r in the '2r 2'in'usin" ba"8

3#th i%ea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbal

actie c2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' can%y8Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbal

.%eas $uber C2ncept

39th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbalactie c2p2un% an% 5ith the echanis 2' ipe%in"

8/17/2019 PPT UTS (2)

46/85

39th i%ea actie c2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' eerescent8

40th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbalactie an% 5ith the echanis 2' interleuin>1 inhibit2r inthe '2r 2' eerescent8

41st i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbalactie an% 5ith the echanis 2' anti>histaine in the '2r2' eerescent8

4n% i%eaAnti>pyretic %ru" 5ith a2nes as herbal actie c2p2un%an% 5ith the echanis 2' leu2trienes inhibit2r in the '2r2' eerescent8

43r% i%ea Anti>pyretic %ru" 5ith hy%r2"el as synthetic actie c2p2un%an% 5ith the echanis 2' re2in" heat by heat trans'er inthe '2r 2' patch8

44th i%eaAnti>pyretic %ru" 5ith enth2l as herbal actie c2p2un%an% 5ith the echanis 2' re2in" heat by heat trans'er inthe '2r 2' l2ti2n8

4#th

i%ea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbal

actie c2p2un% an% 5ith the echanis 2' ipe%in"pr2sta"lan%ins in the '2r 2' syrup8

th

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbal>

.%eas $uber C2ncept r

49 h i%Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate ash b l i % % i h h h i '

8/17/2019 PPT UTS (2)

47/85

49th i%ea herbal actie c2p2un% an% 5ith the echanis 2'ipe%in" pr2sta"lan%ins in the '2r 2' tablet8

#0th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate asherbal actie an% 5ith the echanis 2' interleuin>1

inhibit2r in the '2r 2' tablet8

#1st i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate asherbal actie an% 5ith the echanis 2' anti>histainein the '2r 2' tablet8

#n% i%eaAnti>pyretic %ru" 5ith a2nes as herbal actie an% 5iththe echanis 2' leu2trienes inhibit2r in the '2r 2'tablet8

#3r% i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate asherbal actie c2p2un% an% 5ith the echanis 2'ipe%in" pr2sta"lan%ins in the '2r 2' capsule8

#4th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate asherbal actie an% 5ith the echanis 2' interleuin>1inhibit2r in the '2r 2' capsule8

##th i%ea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as

herbal actie an% 5ith the echanis 2' anti>histainein the '2r 2' capsule8Anti>pyretic %ru" 5ith a2nes as herbal actie an% 5ith

C2binin" E/li i ti H b l

8/17/2019 PPT UTS (2)

48/85

/liinatin" HerbalAntipyretic

!in%ap C2ncept

8/17/2019 PPT UTS (2)

49/85

C2ncept "enerati2n

8/17/2019 PPT UTS (2)

50/85

Generate%

C2ncepts

5iscover t#eneeds• Cust2er• Supplier• .nternal

researcher• C2petit2r

5evelopingIdeas• .a"inati2n• !2%ifcati2n

Innovation• Actie C2p2un%• la2ur• 2r 2' the

pr2%uct• /ectieness

Pre&$valuat

Ideas Number ConceptAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2

8/17/2019 PPT UTS (2)

51/85

Parasetamol an% 5ith the echanis 2' ipe%in" pr2sta"lan%ins in thesyrup8

IbuprofenAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' ipe%in" pr2sta"lan%ins in the

syrup8

'st ideaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' ipe%in" pr2sta"lan%ins in thesyrup8

;nd ideaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' interleuin>1 inhibit2r in thesyrup8

9rd idea Anti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' anti>histaine in the '2r 2' s

8t# ideaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' inin anta"2nis in the '2r 2

t# ideaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' leu2trienes inhibit2r in thesyrup8

(t# ideaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' ipe%in" pr2sta"lan%ins in thesyrup8

.%eas $uber C2ncept

9th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p2

ith th h i ' i i t i i th ' '

8/17/2019 PPT UTS (2)

52/85

9 i%ea5ith the echanis 2' inin anta"2nis in the '2r 2' syr

10th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' leu2trienes inhibit2r in the '2r 2

11th

i%ea

Anti>pyretic %ru" 5ith paraceta2l as cheical actie c2

an% 5ith the echanis 2' ipe%in" pr2sta"lan%ins in thecapsule8

1th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' interleuin>1 inhibit2r in thecapsule8

13th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' anti>histaine in the '2r 2' c

14th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' inin anta"2nis in the capsule8

1#th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' leu2trienes inhibit2r in thecapsule8

16th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' ipe%in" pr2sta"lan%ins in thecapsule8Anti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p2

.%eas $uber C2ncept


ith th h i ' i i t i i th ' '

8/17/2019 PPT UTS (2)

53/85

19 i%ea5ith the echanis 2' inin anta"2nis in the '2r 2' cap

0th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' leu2trienes inhibit2r in the capsule8

1st i%ea Anti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' ipe%in" pr2sta"lan%ins in thetablet8

n% i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' interleuin>1 inhibit2r in thetablet

3

r%

i%ea

Anti>pyretic %ru" 5ith paraceta2l as cheical actie c2

an% 5ith the echanis 2' anti>histaine in the '2r 2' ta

4th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' inin anta"2nis in the '2r 2

#th i%eaAnti>pyretic %ru" 5ith paraceta2l as cheical actie c2an% 5ith the echanis 2' leu2trienes inhibit2r in thetablet8

6th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' ipe%in" pr2sta"lan%ins in thetablet8Anti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p2

.%eas $uber C2ncept


ith the echanis 2' inin anta"2nis in the '2r 2' tab

8/17/2019 PPT UTS (2)

54/85

5ith the echanis 2' inin anta"2nis in the '2r 2' tab

30th i%eaAnti>pyretic %ru" 5ith ibupr2'en as cheical actie c2p25ith the echanis 2' leu2trienes inhibit2r in the '2r 2

31st

i%ea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herb

c2p2un% an% 5ith the echanis 2' ipe%in" pr2sta"lthe '2r 2' in'usin" ba"8

3n% i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbc2p2un% an% 5ith the echanis 2' interleuin>1 inhibit'2r 2' in'usin" ba"8

33r% i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbc2p2un% an% 5ith the echanis 2' anti>histaine in

2' in'usin" ba"8

34th i%eaAnti>pyretic %ru" 5ith a2nes as herbal actie c2p25ith the echanis 2' leu2trienes inhibit2r in the in'usin" ba"8

3#th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbc2p2un% an% 5ith the echanis 2' ipe%in" pr2sta"lthe '2r 2' can%y8

36th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbc2p2un% an% 5ith the echanis 2' interleuin>1 inhibit'2r 2' can%y8

8/17/2019 PPT UTS (2)

55/85

.%eas $uber C2ncept

39th i%eaAnti>pyretic %ru" 5ith hy%r2"el as synthetic actie c2an% 5ith the echanis 2' re2in" heat by heat trans'e'2r 2' patch8

40th i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbac2p2un% an% 5ith the echanis 2' ipe%in" pr2sta"in the '2r 2' syrup8

41st i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbac2p2un% an% 5ith the echanis 2' interleuin>1 inhthe '2r 2' syrup8

4n% i%eaAnti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbac2p2un% an% 5ith the echanis 2' anti>histaine in t2' syrup8

43r% i%eaAnti>pyretic %ru" 5ith a2nes as herbal actie c2p2u

5ith the echanis 2' leu2trienes inhibit2r in the '2r 2

8/17/2019 PPT UTS (2)

56/85

C2ncept Screenin" an% N2inin"

2ncept creen n" anN2inin"

8/17/2019 PPT UTS (2)

57/85

N2inin"

A'ter 5e "enerate the c2ncepts 5e 5ill select the 'easible 2b;ect an% eliinate the ip2ssible8

&his step is calle% a c2ncept screenin"8 &his etintr2%uce% by Stuart u"h 2n 19*0 an% calle%Decisi2n !ain" !atri:

&his phase ain 2b;ectie is t2 narr25 %25n thec2ncepts that e:iste% an% re%uce the any pr2%ucc2ncept i%eas "enerate% t2 a relatie 'e5 that 5ill

a%%iti2nal refneent an% analysis

C2ncept Screenin" an% N2inin"? Steps

8/17/2019 PPT UTS (2)

58/85

• Selecti2n criteria ust relate t2 ey cust2ernee%s8

• Selecti2n criteria selecti2n is %2ne 2n the basis 2'thin"s that %istin"uish each c2ncept i%eas8

• .%ea c2ncepts 5ill be c2pare% t2 bencharbran% as re'erence c2ncept8

repare the

selecti2nscreenin"atri:8

• O is "ien '2r better than re'erence c2ncept

• M is "ien '2r c2ncepts that are 52rse than re'erec2ncept

• 0 is "ien '2r c2ncepts that are e@ual than re'erec2ncept8

ate thec2ncepts8

• anin" the c2ncepts is nee%e% t2 be %2ne as2b;ectiely as p2ssible usin" the c2ncept ratin"8

• C2ncept ratin" 2' any i%eas '2r each selecti2n critthen is a%%e% t2 the t2tal sc2re8

an the

c2ncepts

C2ncept Screenin" an% N2inin"? Steps (c

8/17/2019 PPT UTS (2)

59/85

C2ncept Screenin" an% N2inin"? Steps (c

• .t is nee%e% t2 fn% i' there are any "enerally "22c2ncepts that are %25n"ra%e% by 2ne 'eature anfn% i' it p2ssible '2r c2ncepts t2 be c2bine% presere the Fbetter than 'eatures 5hilesiultane2usly re2in" any F52rse than 'eatu

C2bine Eipr2e thec2ncepts

• .%eas 5ith the t2tal sc2re is bel25 than 1 are

%eci%e% n2t t2 be realiPe% 5hile the c2ncept 5italue ab2e than 1 are bein" c2ntinue% by %2in"the er"er 2' certain c2ncepts t2 ipr2e the ra2' that c2ncept8

Select 2ne 2r2re c2ncepts '2r

'urtherrefneent an%

analysis

• All tea ebers nee% t2 reect 2n current resu

t2 fn% i' it is c2'2rtable en2u"h 5ith the %ecisithat hae been a%e8 .' its n2t c2'2rtable theanu'acturer %esi"ner tea ebers sh2ul% f

eect 2n the

results an%pr2cess

C2ncept Screenin" an% N2inin"? Selectioncriteria

8/17/2019 PPT UTS (2)

60/85

criteria

/asy t2 ,se

a8 /asy t2 s5all25b8 /asy t2 carry

c8 ractical in serin"%8 Sae t2 be c2nsue% at any tie

/asy t2!anu'acture

a8 Siple c2p2siti2nb8 /asy t2 pr2%uce

r2%uct/ectieness

t2 Decreaseeer

a8 Actie c2p2un% that heal either inaat2ry 2Hyp2thalaus

b8 /asy t2 release in the b2%yc8 C2ntainin" ri"ht a2unt 2' %2sa"e

Si%e /ects

a8 Dr25sinessb8 St2ach crapc8 $ausea%8 Drie% 2uth

e8 Hea%ache'8 S2re thr2at8 Seere %iPPiness

C2ncept Screenin" an% N2inin"?Matrix Of Concept Screening

8/17/2019 PPT UTS (2)

61/85

Matrix Of Concept Screening

Ideas$asy to

6se

$asy to

!anufacture

Product$Aectivenes

s

Side

$Aects

Scor

e

R

Parasetamol

0 0 0 0 0 e

Ibuprofen

0 0 0 >1 >1e

'st idea 0 0 0 0 0 $

;nd

idea 0 0 0 0 0 $9rd idea 0 0 0 0 0 $8t# idea 0 0 0 0 0 $t# idea 0 0 0 0 0 $(t# idea 0 0 0 >1 >1 $>t# idea 0 0 0 >1 >1 $7t# idea 0 0 0 >1 >1 $=t# idea 0 0 0 >1 >1 $'1 >1 $

t# > >


8/17/2019 PPT UTS (2)

62/85


Ideas$asy to

6se

$asy to

!anufacture

Product$Aectivenes

s

Side

$Aects

Scor

e

R

Parasetamol

0 0 0 0 0 e

Ibuprofen

0 0 0 >1 >1e

'8t# idea 0 >1 0 0 >1 $

't#

idea 0 >1 0 0 >1 $'(t# idea 0 >1 0 >1 > $'>t# idea 0 >1 0 >1 > $'7t# idea 0 >1 0 >1 > $'=t# idea 0 >1 0 >1 > $

;1 0 >1 > $

;'st idea 0 >1 0 0 >1 $;;nd idea 0 >1 0 0 >1 $

rd > >


8/17/2019 PPT UTS (2)

63/85


Ideas$asy to

6se

$asy to

!anufacture

Product$Aectivenes

s

Side

$Aects

Scor

e

R

Parasetamol

0 0 0 0 0 e

Ibuprofen

0 0 0 >1 >1e

;>t# idea 0 >1 0 >1 > $

;7t#

idea 0 >1 0 >1 > $;=t# idea 0 >1 0 >1 > $91 0 >1 > $9'st idea >1 1 0 1 1 G9;nd idea >1 1 0 1 1 G99rd idea >1 1 >1 1 0 $98t# idea >1 1 >1 1 0 $9t# idea 1 >1 >1 1 0 $9(t# idea 1 >1 >1 1 0 $

t# > >


8/17/2019 PPT UTS (2)

64/85


Ideas$asy to

6se

$asy to

!anufacture

Product$Aectivenes

s

Side

$Aects

Scor

e

R

Parasetamol

0 0 0 0 0 e

Ibuprofen

0 0 0 >1 >1e

8

8/17/2019 PPT UTS (2)

65/85

that passed in concept screening

Ideas Concept

9'

st

idea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herba

c2p2un% an% 5ith the echanis 2' ipe%in" pr2sta"lanthe '2r 2' in'usin" ba"8

9;nd

idea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbac2p2un% an% 5ith the echanis 2' interleuin>1 inhibit2'2r 2' in'usin" ba"8

8<

t#

idea


c2p2un% an% 5ith the echanis 2' ipe%in" pr2sta"lanthe '2r 2' syrup8

8'st

idea

Anti>pyretic %ru" 5ith ethyl p>eth2:ycinnaate as herbac2p2un% an% 5ith the echanis 2' interleuin>1 inhibit2'2r 2' syrup8

8;nd

idea


c2p2un% an% 5ith the echanis 2' anti>histaine in the syrup8

89rd Anti> retic %ru 5ith a2nes as herbal actie c2 2un% a

8/17/2019 PPT UTS (2)

66/85

C2ncept Sc2rin" an%Selecti2n

C2ncept Sc2rin"

8/17/2019 PPT UTS (2)

67/85

A'ter the c2ncept bein" screene% an%

;2ine% 5e rate each c2ncept ratin" '2r alc2ncepts 'r2 all selecti2n criteria 5assue% up an% becae the net sc2re

&he c2ncept that has thehi"hest sc2re 52ul% be

ch2sen as the bestc2ncept

C2ncept Sc2rin"

8/17/2019 PPT UTS (2)

68/85

Anti>pyretic %ru" 5ith herb actie c2p2un% an% 5ith thechanis 2' ipe%in" pr2sta"lan%ins in the '2r 2' sy

Anti>pyretic %ru" 5ith herb actie c2p2un% an% 5itthe echanis 2' ipe%in" leu2cyt pyr2"enes in th'2r 2' syrupAnti>pyretic %ru" 5ith herb actie c2p2un% an% 5the echanis 2' ipe%in" histaine in the '2r 2

syrup

Anti>pyretic %ru" 5ith herb actie c2p2un% an% 5itthe echanis 2' ipe%in" inin in the '2r 2' syru

Anti>pyretic %ru" 5ith herb actie c2p2un% an% 5ith th

echanis 2' ipe%in" leu2trienes in the '2r 2' syru

Practically to use /;

8/17/2019 PPT UTS (2)

69/85

1? r2%uct can t be c2nsue% anytie nee% certain

instruents t2 be c2nsue% an% har% t2 s5all25

? r2%uct cant be c2nsue% anytie nee% certaininstruents t2 be c2nsue% an% easy t2 s5all253? Can be %irectly c2nsue% nee% certain instruent t2 bec2nsue% an% har% t2 s5all254? Can be %irectly c2nsue% nee% certain instruent t2 bec2nsue% an% easy t2 s5all25

!anufacturability /'B01? Har% t2 pr2%uce? $2t that har% t2 pr2%uce

3? $2t that easy t2 pr2%uce4? /asily pr2%uce

$Aectiveness to reduce fever

8/17/2019 PPT UTS (2)

70/85

/9

8/17/2019 PPT UTS (2)

71/85

Criteria

Sub&Criteria

Practicalityto 6se

!anufacturability

$Aectiveness to reduce

*everSide $Ae

Qei"hts 0= 1#= 30= 0=

esultsatin

"Qei"hte% Sc2re

atin"Qei"ht

e%Sc2re

atin"

Qei"hte%

Sc2re

atin"

Qei"% Sc

4nti&pyretic drugit# et#yl p&

met#oxycinnamateas #erbal active

compound and it#t#e mec#anism of

impedingprostaglandins in

t#e form of infusingbag-

084 4 086 4 18 4 08

4nti&pyretic drugit# et#yl p&met#oxycinnamate

8/17/2019 PPT UTS (2)

72/85

$Aectivenes

C2ncept Sc2rin" (c2nt)

8/17/2019 PPT UTS (2)

73/85

Criteria

Sub&Criteria

Practicalityto 6se

!anufacturability

$Aectiveness to reduce

*everSide $Ae

Qei"hts 0= 1#= 30= 0=

esultsatin

"

Qei"hte%

Sc2reatin"

Qei"hte%

Sc2re

atin"

Qei"hte% Sc2re

atin"

Qei"% Sc2

4nti&pyretic drugit# et#yl p&

met#oxycinnamate

as #erbal activecompound andit# t#e

mec#anism of anti&#istamine in t#eform of syrup-

4 08* 3 084# 4 18 4 08*

4nti&pyretic drug

it# avones as#erbal active

compound and

Selecte% C2ncept

8/17/2019 PPT UTS (2)

74/85

Idea$asy to

6se

$asy to!anufactur

e

$Aectiveness $

4nti&pyretic drugit# it# et#yl p&met#oxycinnamateand avones as #erbactive compoundand it# t#e

mec#anism ofimpedingprostaglandins, asinterleu%in&'in#ibitor, as anti&#istamine, and as

leu%otrienesin#ibitor in t#e form

/asy t2carry "22%

t2 bec2nsue%anytiean%practical

Sipleanu'acture

pr2cesseasy %ru"c2p2siti2nanu'acturepr2cess

/ectieDr2s

8/17/2019 PPT UTS (2)

75/85

C2ncept &estin"

C2ncept &estin"

8/17/2019 PPT UTS (2)

76/85

• ARrin" 5hether the ch2sen

c2ncept can be accepte% bycust2ers8

• &est %2ne thr2u"h sureys?

! 2pulati2n? #6 pe2ple (4*= 2' thestu%ents)

! 2rat? 2nline @uesti2nnaires

! C2ncept %escribe% in 5ritten '2r

Cust2ers esp2nses

8/17/2019 PPT UTS (2)

77/85

• 91= resp2n%ents sh25

interest in buyin" li@uiherbal antipyretic insachet 5ith naturals5eetener8

• &he c2ncept in%ee% ft

5ithin the cust2ersnee%s s2 it can c2pe5ith 2ther e:istin"antipyretic pr2%ucts8

Interest in Cuying LiDuid .erbal 4ntipyretic in Sac#et ,it# Natural S,eetener

Se

s

erceptual !ap

8/17/2019 PPT UTS (2)

78/85

(racticality t2 ,se

!anu'acturability

/9ectieness

Si%e /9ect 0

4

Herbal Antipyret

(araceta62l

.bupr2'en

&2la) An"in Si%2Antan"in NG

erceptual !ap

8/17/2019 PPT UTS (2)

79/85

.erbal

4ntipyret

ic

Paracetam

olIbuprofen

)ola% 4ngin

Sidomuncul4ntan

Practicality

to 6se4 3 3 4

!anufactura

bility 3 3$Aectiveness 4 4 4 4

Side $Aect 4 1 1 3

erceptual !ap

8/17/2019 PPT UTS (2)

80/85

• Practicality to 6se: .n li@ui% '2r &2la An"in an%Antan"in 5ill be paca"e% in sachet 5hich is easy t2

carry an% can be c2nsue% anytie 5hile paracetaan% ibupr2'en are usually paca"e% in b2ttle there'2r

less practical t2 c2nsue8

• !anufacturability: Synthetic %ru"s re@uire a l2n"pr2cess 2' pr2%ucti2n 5hich eans it re@uires 2rea%ance% achinery '2r 2re c2plicate% pr2cessesan% re@uires 2re c2st8 !ean5hile herbal e%icine 5n2t re@uire t22 uch a%ance% achinery8

erceptual !ap

8/17/2019 PPT UTS (2)

81/85

• $Aectiveness: Synthetic %ru"s are alrea%y establishe%eectie antipyretics 5hich are c22nly c2nsue%8

&2la An"in an% Antan"in h25eer %2 n2t '2cus in itsantipyretic pr2perties t2 l25er 'eer but rather t2 pree2r cure 'r2 catchin" c2l%8 &here'2re their eectienesin l25erin" 'eer is still l25er8

• Side eAect: Despite their eectieness synthetic %ru"are sh25n t2 hae 2re %an"er2us p2ssible si%e eects!ean5hile herbal e%icine are less liely t2 hae such%an"er2us si%e eects because 2' their natural pr2perti

8/17/2019 PPT UTS (2)

82/85

C+$C-,S.+$

C2nclusi2n1 Herbal antipyretic %ru"s hae less si%e eects be

8/17/2019 PPT UTS (2)

83/85

18 Herbal antipyretic %ru"s hae less si%e eects bec2pare% 5ith synthetic antipyretic8

8 C2nsuin" herbal antipyretics can be an alternati2r%er t2 preent the %aa"es 2' c2nsuin" synthantipyretic %ru"s in the l2n" ter8

38 r2 resp2n%ents stateents 5e select seeralnee%s that ust be c2ntaine% in 2ur pr2%uct8 &herareT 100= 'resh herbal>a%e antipyretic herbalantipyretic 5hich 52rs @uicly an% eectielyantipyretic 5ith2ut artifcial s5eetener antipyretic5hich is n2t 2nly a2r%able but als2 aailable in a

%ru" st2res48 !2re2er resp2n%ents lie herbal antipyretic 5hic

C2nclusi2n# &h % t t l t % b % th

8/17/2019 PPT UTS (2)

84/85

#8 &he pr2%ucts c2ncepts are ealuate% base% 2n theparaeters 2' practicality t2 use anu'acturability

eectieness an% si%e eects868 ase% 2n the sc2rin" 'r2 the a'2reenti2ne% paraet

the selecte% c2ncept 2' the pr2%uct is antipyretic %ru" 5herb actie c2p2un% an% 5ith the echanis 2' ipepr2sta"lan%ins in the '2r 2' syrup8

78 A'ter c2ncept testin" thr2u"h @uesti2nnaires it is '2un%the selecte% c2ncept can be accepte% by pr2spectiecust2ers seen 'r2 91= 2' the sh25in" interest inbuyin" the herbal antipyretic8

8/17/2019 PPT UTS (2)

85/85

&han 2u

ppt uts (2)

Documents